US › Healthcare

Organon & Co (OGN)

US · Healthcare · Drug Manufacturers - General

$13.560.00%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$1.6M
Revenue YoY
-99.9%
Net profit
$108,000
Profit YoY
-99.9%
EPS
$0.80
EPS estimate
$0.85
Net margin
6.9%

EPS came in at 0.80 against a street estimate of 0.85 — a miss of 5.9%.

Key statistics

Market cap
$3.56B
P/E
17.4
Forward P/E
5.1
P/B
3.54
Book value
$3.44
EPS (TTM)
$0.78
Dividend yield
0.59%
52-week high
$13.60
52-week low
$5.68
50-day MA
$13.47
200-day MA
$9.55
Beta
1.54

Analyst view

Analysts rate Organon & Co a hold (2 buy, 3 hold, 2 sell out of 7) with an average price target of $11.25.

Shareholding

Insiders
0.47%
Institutions
77.80%

Largest institutional holders

FundStake
BlackRock Inc12.08%
Vanguard Portfolio Management, LLC8.32%
Vanguard Capital Management, LLC4.47%
State Street Corp3.79%
LSV Asset Management2.76%
Millennium Management LLC2.58%
Kahn Brothers & CO Inc /DE/2.11%
Canada Pension Plan Investment Board1.91%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q3 20262026-07-31
Quarterly report · Q2 20262026-07-31
Shareholder vote results · Q3 20262026-07-23
Company announcement · Q3 20262026-07-17
Board / officer change · Q2 20262026-06-11
Quarterly report · Q1 20262026-05-04
Proxy statement · Q2 20262026-04-24
Annual report FY20252026-02-24

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Organon & Co — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.